Abstract: A detection structure, a display panel, a detection device and a detection system, the detection structure is located in display panel, and detection structure includes test units and groups of first connecting lines; each test units includes chip bonding part, test pin parts located at chip bonding part, and groups of second connecting lines; in each test units, first end of each group in groups of second connecting lines is connected with test pin parts, and second end of each group of second connecting lines is connected with chip bonding part; in any two adjacent test units in test units, two adjacent test pin parts are respectively connected with first end and second end of one group of first connecting lines; and when detection structure is used in lightening test, at least two test units arranged at intervals are configured for being electrically connected with detection device respectively.

Abstract: The present invention relates to a kinase inhibitor, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention further relates to pharmaceutical compositions comprising the kinase inhibitor, as well as to using said compounds and compositions to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGF, PDGF, and/or VEGFR2 kinase activity in cells or a subject, and/or to a use and method for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGF, PDGF, and/or VEGFR2 activity in a subject.

Abstract: An array substrate having a display area, a peripheral area, and a bonding area inside the peripheral area is provided. The array substrate includes a bonding pad in the bonding area, the bonding pad configured to be connected to a peripheral circuit through a bonding connector, a test signal line including a first portion and a second portion. The first portion is in the peripheral area and substantially surrounds the display area. The first portion is electrically connected to the bonding pad. The first portion is completely inside the array substrate and has no exposed terminal. The second portion is in the bonding area. A first terminal of the second portion is electrically connected to the bonding pad. A second terminal of the second portion has an end along an edge of the array substrate in the bonding area.

Abstract: Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.

Abstract: The disclosure relates to a display panel. The display panel may include a first substrate, a second substrate opposite the first substrate, a liquid crystal layer between the first substrate and the second substrate, a first electrode on a side of the first substrate facing the liquid crystal layer, a second electrode between the liquid crystal layer and the first electrode, the second electrode being insulated from the first electrode, and an anti-peeping electrode on a side of the second substrate facing the liquid crystal layer.

Abstract: An array substrate, a display panel, a display device, and a manufacturing method for an array substrate are provided. The array substrate includes a pixel unit group which includes a first pixel and a second pixel; the first pixel includes a first pixel electrode, a first switching element, and a first connection portion extending and protruding from the first pixel electrode; the second pixel includes a second pixel electrode, a second switching element, and a second connection portion extending and protruding from the second pixel electrode; the first pixel electrode and the first switching element are electrically connected to each other via the first connection portion; the second pixel electrode and the second switching element are electrically connected to each other via the second connection portion; and an extension length of the first connection portion is not equal to an extension length of the second connection portion.

Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.

Abstract: A method of preparing a graphene circuit pattern, a substrate and an electronic product are disclosed. The method of preparing a graphene circuit pattern includes: immersing a metal circuit pattern in a graphene oxide solution to cause a redox reaction between the metal circuit pattern and graphite oxide, thereby forming the graphene circuit pattern. The graphene circuit pattern may be directly formed at a location of the metal circuit pattern, and is simple in production process, low in cost, and suitable for mass production.

Abstract: The present disclosure provides a cross-blockchain data access method, apparatus and system, and a computer readable medium. The method comprises: sending an authorizing blockchain apparatus a block data request carrying a requesting blockchain apparatus identifier and authorization information, so that the authorizing blockchain apparatus verifies whether the authorization information corresponding to locally-stored requesting blockchain apparatus identifier is matched with the authorization information in the block data request; receiving block data sent by the authorizing blockchain apparatus and corresponding to the block data request, the block data being sent after the authorizing blockchain apparatus verifies that the authorization information corresponding to locally-stored requesting blockchain apparatus identifier is matched with the authorization information in the block data request.

Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).

Abstract: Event processing associated with a smart device is disclosed, including: receiving an indication of an event detected by a function module associated with a smart device; determining, based at least in part on event registration information, that an event message is to be sent to a cloud device; and sending the event message to the cloud device. Event processing associated with a smart device also includes: receiving an indication of an event detected by a first function module associated with a smart device; determining, based at least in part on event registration information, that a control message is to be sent to a second function module associated with the smart device; and sending the control message to the second function module associated with the smart device.

Abstract: The present application discloses a backlight module for a display apparatus. The backlight module for a display apparatus includes a light guide plate; and a light transmittance control layer on the light guide plate configured to receive light from the light guide plate and modulate light intensity of the light from the light guide plate. The light transmittance control layer includes a light transmittance control material having a variable light transmissivity. Light transmittance in a plurality of regions of the light transmittance control layer is individually controllable.

Abstract: Establishing a connection is disclosed including acquiring an authentication code, sending data including the authentication code to a management server, receiving parameter information sent back by the management server after the management server performed a successful authentication using the data including the authentication code, and establishing, using the parameter information, a channel to a connection server.

Abstract: An array substrate, a display device, and a method for repairing a broken wire of an array substrate are disclosed. The array substrate includes a substrate, a plurality of sub-pixel units on the substrate, and a wire and a first conductive light-blocking pattern between two adjacent sub-pixel units of the plurality of sub-pixel units. The first conductive light-blocking pattern is electrically insulated from the wire, and the first conductive light-blocking pattern includes two first regions. Orthographic projections of the two first regions on the substrate overlap with an orthographic projection of the wire on the substrate.

Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR? and/or PDGFR? kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.

Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.

Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.

Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.

Abstract: The present application discloses a backlight module for a display apparatus. The backlight module for a display apparatus includes a light guide plate; and a light transmittance control layer on the light guide plate configured to receive light from the light guide plate and modulate light intensity of the light from the light guide plate. The light transmittance control layer includes a light transmittance control material having a variable light transmissivity. Light transmittance in a plurality of regions of the light transmittance control layer is individually controllable.

Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.